6
KLBF0206.TXT

KLBF
Kalbe Farma
Af          :
Sector Code : 53
Sector Name : PHARMACEUTICALS

(In thousand rupiah except Par Value, Closing Price and Ratios)

Financial Statement Date    : 30-Jun-2002
Fiscal Year Ends            : Dec
Months Covered in Income St : 6

Summary of Balance Sheet
  Receivables               :     551,921,390.91
  Inventories               :     320,092,873.50
  Current Assets            :   1,240,237,429.70
  Fixed Assets              :     447,350,198.11
  Other Asstes              :      19,602,503.48
  Total Assets              :   2,077,523,709.36
  Current Liabilities       :     472,437,879.70
  Longterm Liabiities       :     982,573,147.31
  Total Liabilities         :   1,455,011,027.01
  Authorized                :       8,500,000.00
  Paid-up Capital           :     406,080,000.00
  Par Value                 :                100
  Paid-up Capital Shares    :       4,060,800.00
  Retained Earnings         :      47,355,412.35
  Total Equity              :     470,721,250.11
  Minority Interest         :     151,791,432.24

Summary of Income Statement
  Total Sales               :   1,248,532,748.92
  Cost of Good Sold         :     617,259,340.37
  Gross Profit              :     631,273,408.54
  Operating Profit          :     277,531,699.00
  Other Income              :      87,185,842.85
  Eearning Before Tax       :     364,717,541.85
  Tax                       :     107,562,372.43
  Net Income                :     231,530,205.28
  Closing Price             :             410.00

Per Share Data (Rp)
  Eps                       :             114.03
  Book Value                :             115.92

Financial Ratios
  Debt Equity Ratio (X)     :               3.09
  Roa (%)                   :              22.29
  Roe (%)                   :              98.37
  Npm (%)                   :              18.54
  Opm (%)                   :              22.23

Cash Flow
  CF from Operating Activities                        :      98,979,011.24
  CF from Investing Activities                        :     -30,118,170.44
  CF from Financing Activities                        :     -40,222,161.93
  Net Increase in Cash & Cash Equivalent              :      15,101,344.08
  Cash & Cash Equivalent at The Beginning of The Year :     247,241,482.84
  Cash & Cash Equivalent at The End of The Year       :     262,342,826.91

 
 
 
